pypd-20260630
2026-06-30
--12-31
0001611842
false
Q2
0001611842
2026-01-01
2026-06-30
0001611842
us-gaap:SubsequentEventMember
2026-07-17
2026-07-17
0001611842
us-gaap:SubsequentEventMember
pypd:NewDrugApplicationMember
2026-07-17
2026-07-17
0001611842
pypd:August2024Member
srt:ScenarioForecastMember
2026-08-01
2026-08-31
0001611842
us-gaap:SubsequentEventMember
us-gaap:WarrantMember
2026-07-01
2026-07-31
0001611842
us-gaap:SubsequentEventMember
srt:MaximumMember
2026-07-01
2026-07-31
0001611842
us-gaap:SubsequentEventMember
srt:MinimumMember
2026-07-01
2026-07-31
0001611842
srt:ScenarioForecastMember
2026-08-01
2026-08-31
0001611842
us-gaap:SubsequentEventMember
2026-07-01
2026-07-31
0001611842
2025-01-01
2025-06-30
0001611842
us-gaap:WarrantMember
2025-01-01
2025-06-30
0001611842
us-gaap:WarrantMember
2026-01-01
2026-06-30
0001611842
us-gaap:StockOptionMember
2025-01-01
2025-06-30
0001611842
us-gaap:StockOptionMember
2026-01-01
2026-06-30
0001611842
2026-06-30
0001611842
pypd:June2025Member
2026-01-01
2026-06-30
0001611842
pypd:June2025Member
2026-06-30
0001611842
pypd:August2024Member
2026-01-01
2026-06-30
0001611842
pypd:August2024Member
2026-06-30
0001611842
pypd:April2022OneMember
2026-01-01
2026-06-30
0001611842
pypd:April2022OneMember
2026-06-30
0001611842
pypd:July2022Member
2026-01-01
2026-06-30
0001611842
pypd:July2022Member
2026-06-30
0001611842
pypd:April2022Member
2026-01-01
2026-06-30
0001611842
pypd:April2022Member
2026-06-30
0001611842
pypd:GeneralAndAdministrativeMember
2025-01-01
2025-06-30
0001611842
pypd:GeneralAndAdministrativeMember
2026-01-01
2026-06-30
0001611842
pypd:MarketingAndBusinessDevelopmentMember
2025-01-01
2025-06-30
0001611842
pypd:MarketingAndBusinessDevelopmentMember
2026-01-01
2026-06-30
0001611842
pypd:ResearchAndDevelopmentExpensesMember
2025-01-01
2025-06-30
0001611842
pypd:ResearchAndDevelopmentExpensesMember
2026-01-01
2026-06-30
0001611842
pypd:EmployeesAndNonEmployeesMember
2026-01-01
2026-06-30
0001611842
pypd:EmployeesAndNonEmployeesMember
2026-06-30
0001611842
pypd:EmployeesAndNonEmployeesMember
2025-12-31
2025-12-31
0001611842
pypd:EmployeesAndNonEmployeesMember
2025-12-31
0001611842
us-gaap:StockOptionMember
2026-01-01
2026-06-30
0001611842
pypd:OfficersMember
2026-01-01
2026-06-30
0001611842
us-gaap:CommonStockMember
2026-01-01
2026-06-30
0001611842
us-gaap:WarrantMember
2026-03-06
2026-03-06
0001611842
us-gaap:WarrantMember
2026-01-08
2026-01-08
0001611842
us-gaap:CommonStockMember
2026-01-08
0001611842
pypd:NewWarrantsMember
2026-01-08
0001611842
srt:MinimumMember
us-gaap:CommonStockMember
us-gaap:WarrantMember
2026-06-30
0001611842
srt:MaximumMember
us-gaap:CommonStockMember
us-gaap:WarrantMember
2026-06-30
0001611842
us-gaap:CommonStockMember
pypd:AbeyanceMember
2025-12-01
2025-12-31
0001611842
pypd:AbeyanceMember
2025-12-01
2025-12-31
0001611842
us-gaap:IPOMember
2025-06-16
2025-06-16
0001611842
pypd:NewWarrantsSharesMember
2025-06-16
0001611842
us-gaap:CommonStockMember
pypd:NewWarrantsSharesMember
2025-06-16
0001611842
srt:MinimumMember
pypd:NewWarrantsMember
2025-06-16
0001611842
2025-06-16
0001611842
us-gaap:CommonStockMember
pypd:January2024WarrantsMember
2025-06-16
0001611842
pypd:December2024WarrantsMember
2025-06-16
0001611842
pypd:InducementLetterMember
us-gaap:CommonStockMember
pypd:January2024WarrantsMember
2025-06-16
0001611842
pypd:InducementLetterMember
pypd:January2024WarrantsMember
2025-06-16
0001611842
us-gaap:CommonStockMember
2025-09-04
0001611842
us-gaap:CommonStockMember
2025-06-09
0001611842
pypd:PreFundedWarrantsMember
2025-09-04
0001611842
pypd:PreFundedWarrantsMember
2025-06-09
0001611842
us-gaap:WarrantMember
2025-06-23
0001611842
srt:MaximumMember
us-gaap:WarrantMember
2025-06-16
0001611842
us-gaap:PrivatePlacementMember
2024-12-26
2024-12-26
0001611842
2024-12-26
2024-12-26
0001611842
us-gaap:CommonStockMember
pypd:December2024WarrantsMember
2024-12-26
2024-12-26
0001611842
us-gaap:WarrantMember
2024-12-26
0001611842
us-gaap:WarrantMember
2024-12-26
2024-12-26
0001611842
2024-12-26
0001611842
us-gaap:CommonStockMember
2026-06-30
0001611842
pypd:PreFundedWarrantsMember
2026-06-30
0001611842
pypd:August2024WarrantsMember
2026-01-01
2026-06-30
0001611842
us-gaap:CommonStockMember
pypd:August2024WarrantsMember
2026-06-30
0001611842
pypd:August2024WarrantsMember
2026-06-30
0001611842
us-gaap:CommonStockMember
2025-06-30
0001611842
pypd:PreFundedWarrantsMember
2025-06-30
0001611842
us-gaap:PrivatePlacementMember
2024-08-01
2024-08-01
0001611842
2024-08-01
2024-08-01
0001611842
us-gaap:CommonStockMember
pypd:August2024WarrantsMember
2024-08-01
0001611842
us-gaap:CommonStockMember
pypd:August2024WarrantsMember
2024-08-01
2024-08-01
0001611842
us-gaap:WarrantMember
2024-08-01
0001611842
us-gaap:WarrantMember
2024-08-01
2024-08-01
0001611842
us-gaap:CommonStockMember
2024-08-01
0001611842
us-gaap:CommonStockMember
2024-08-01
2024-08-01
0001611842
pypd:January2024WarrantsMember
2026-01-31
0001611842
pypd:January2024WarrantsMember
2025-06-16
0001611842
us-gaap:CommonStockMember
us-gaap:WarrantMember
2025-05-20
0001611842
us-gaap:WarrantMember
2025-05-20
0001611842
us-gaap:WarrantMember
2024-01-04
2024-01-04
0001611842
2024-01-04
2024-01-04
0001611842
pypd:DefinitiveSecuritiesPurchaseAgreementMember
2024-01-04
0001611842
us-gaap:PrivatePlacementMember
pypd:January2024WarrantsMember
2024-01-04
0001611842
pypd:DefinitiveSecuritiesPurchaseAgreementMember
pypd:January2024WarrantsMember
2024-01-04
0001611842
pypd:DefinitiveSecuritiesPurchaseAgreementMember
pypd:PreFundedWarrantsMember
2024-01-04
0001611842
pypd:DefinitiveSecuritiesPurchaseAgreementMember
2024-01-04
2024-01-04
0001611842
2025-11-26
0001611842
2025-12-31
0001611842
pypd:IsraelInnovationAuthorityOfTheMinistryOfEconomyMember
pypd:ResearchAndDevelopmentExpensesMember
2026-01-01
2026-06-30
0001611842
2025-06-01
2025-06-30
0001611842
2025-06-30
0001611842
2024-12-31
0001611842
us-gaap:RetainedEarningsMember
2025-06-30
0001611842
us-gaap:AdditionalPaidInCapitalMember
2025-06-30
0001611842
us-gaap:RetainedEarningsMember
2025-01-01
2025-06-30
0001611842
us-gaap:CommonStockMember
2025-01-01
2025-06-30
0001611842
us-gaap:AdditionalPaidInCapitalMember
2025-01-01
2025-06-30
0001611842
us-gaap:RetainedEarningsMember
2024-12-31
0001611842
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001611842
us-gaap:CommonStockMember
2024-12-31
0001611842
us-gaap:RetainedEarningsMember
2026-06-30
0001611842
us-gaap:AdditionalPaidInCapitalMember
2026-06-30
0001611842
us-gaap:RetainedEarningsMember
2026-01-01
2026-06-30
0001611842
us-gaap:AdditionalPaidInCapitalMember
2026-01-01
2026-06-30
0001611842
us-gaap:RetainedEarningsMember
2025-12-31
0001611842
us-gaap:AdditionalPaidInCapitalMember
2025-12-31
0001611842
us-gaap:CommonStockMember
2025-12-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: August 2026 (Report No. 2)
Commission File Number: 001-38428
PolyPid Ltd.
(Translation of registrant’s name into English)
18 Hasivim Street
Petach Tikva 495376, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) consists of PolyPid Ltd.’s (the “Company”): (i) Interim Condensed Consolidated Financial Statements as of June 30, 2026, which is attached hereto as Exhibit 99.1; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2026, which is attached hereto as Exhibit 99.2.
The contents of this Form 6-K are incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, File No. 333-284376 and File No. 333-289034) and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703, File No. 333-280662, File No. 333-289570 and File No. 333-298261) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | POLYPID LTD. |
| | | |
| Date: August 12, 2026 | By: | /s/ Dikla Czaczkes Akselbrad |
| | | Name: | Dikla Czaczkes Akselbrad |
| | | Title: | Chief Executive Officer |